Genmark Diagnostics (GNMK) 13.51 $GNMK
3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 11:01AM CST
2015 is forecasted to be a transition year for the medical instruments sector.
GNMK: 13.51 (+0.21), DXCM: 62.68 (+0.74), TNDM: 13.16 (+0.25)
Commit To Purchase GenMark Diagnostics At $10, Earn 8.1% Annualized Using Options
at The Street - Mon Feb 09, 10:36AM CST
Investors considering a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $13.02/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GNMK: 13.51 (+0.21)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Will Waters (WAT) Surprise Q4 Earnings on Innovations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 11:50AM CST
Waters Corporation (WAT) is scheduled to report fourth-quarter 2014 results before the opening bell on Jan 27, 2015.
XENT: 23.06 (+0.46), GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21), WAT: 119.86 (+0.71)
Global Diagnostic Markets for Women's Health Market to 2018: Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing
M2 - Fri Jan 16, 9:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/hdjx99/diagnostic) has announced the addition of the "Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)" report to their offering. The women's health arena, both therapeutics and diagnostics, has grown considerably as a specialty medical field. Once limited to obstetrics and gynecology, it now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. At many clinics and practices focused on the health of women, a range of specialties are offered, which often results in a need for specific types of women's health-related testing. Generally, and from a perspective on women's health, diagnostics are playing an ever increasing role. Worldwide, women are living longer than men. There is a need to improve the understanding of the differences, in terms of health, between the sexes and to translate that knowledge into improved medical diagnostics, practice and therapies. Women's Health Diagnostic Markets analyzes the current and potential world markets for key diagnostic tests targeted at women's health. This report generally forecasts future market growth for these tests to 2018. Market segments covered include the US, Europe, China, Brazil, Japan and rest of world markets. Over the next few decades, comprehensive genomics-based health care should be the norm in the US and much of Europe. In the next decade, genetic tests will routinely predict individual susceptibility to disease. Diagnoses of many conditions will be much more thorough and specific than now. The report gives insight into understanding the molecular basis of disease. Women's Health Diagnostic Markets also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Developments in Women's Health Diagnostics 4 Pregnancy and Ovulation 5 Bone Density Testing 6 Prenatal Screening 7 Ultrasound 8 Mammography 9 Pap Smears 10 Colposcopy 11 HPV Testing 12 Ovarian Cancer 13 Urinary Tract Infections 14 Neonatal Jaundice 15 Autoimmune Disease 16 Cystic Fibrosis Companies Mentioned - GE Healthcare - GenMark Diagnostics - Hologic - Immco Diagnostics - Luminex - Nova Biomedical - Philips Healthcare - Siemens Healthcare - Somagen Diagnostics For more information visit http://www.researchandmarkets.com/research/hdjx99/diagnostic
GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21)
GE Extends Debt Financing to GenMark to Spur Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 10:10AM CST
GE Capital's Healtcare Financial Services, a division of General Electric Company (GE), recently augmented the liquidity of GenMark Diagnostics, Inc. (GNMK).
GNMK: 13.51 (+0.21), GD: 137.61 (-0.54), GE: 25.15 (+0.26), NOC: 167.14 (-0.15)
GE Capital's Healthcare Financial Services agents USD40m secured credit facility for GenMark Diagnostics
M2 - Wed Jan 14, 6:04AM CST
GE Capital announced on Tuesday that its Healthcare Financial Services business, a source of capital for the US healthcare market, has served as administrative agent on a senior secured credit facility of up to USD40m for GenMark Diagnostics Inc (Nasdaq:GNMK), a provider of automated, multiplex molecular diagnostic testing systems.
GNMK: 13.51 (+0.21), GE: 25.15 (+0.26)
GE Capital Agents $40 Million Credit Facility for GenMark Diagnostics
Business Wire - Tue Jan 13, 7:00AM CST
GE Capital's Healthcare Financial Services business has served as administrative agent on a senior secured credit facility of up to $40 million for GenMark Diagnostics, Inc. (NASDAQ:GNMK), comprised of a multi-tranched $35 million venture loan facility and a $5 million asset-based revolving credit facility. GE Capital Markets served as sole lead arranger and bookrunner.
GNMK: 13.51 (+0.21), GE: 25.15 (+0.26)
GenMark reports preliminary results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 3:19PM CST
GNMK: 13.51 (+0.21)
GenMark Announces Completion of ePlex(TM) Development and Preliminary Q4 Financial Results
Business Wire - Mon Jan 12, 3:05PM CST
--Fourth Quarter Revenue Expected to be $9.8 million, Up 52% Versus Prior Year
GNMK: 13.51 (+0.21)
GenMark Diagnostics to Present at the 2015 J.P. Morgan Healthcare Conference
Business Wire - Tue Dec 30, 3:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2015 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, CA on Tuesday, January 13, 2015. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 9:30 am Pacific Time. The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 13.51 (+0.21), JPM: 59.67 (+0.10)
Insider Trading Alert - GNMK, RLOG And NBY Traded By Insiders
at The Street - Tue Dec 09, 10:38AM CST
Stocks with insider trader activity include GNMK, RLOG and NBY
GNMK: 13.51 (+0.21), RLOG: 3.59 (unch), NBY: 0.56 (unch)
Molecular Diagnostics in Infectious Disease Testing 2014
M2 - Thu Nov 20, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/zbf7zn/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing 2014" report to their offering. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE For more information visit http://www.researchandmarkets.com/research/zbf7zn/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)
M2 - Tue Nov 18, 4:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/pr8g7c/diagnostic) has announced the addition of the "Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)" report to their offering. The women's health arena, both therapeutics and diagnostics, has grown considerably as a specialty medical field. Once limited to obstetrics and gynecology, it now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. At many clinics and practices focused on the health of women, a range of specialties are offered, which often results in a need for specific types of women's health-related testing. Generally, and from a perspective on women's health, diagnostics are playing an ever increasing role. Worldwide, women are living longer than men. There is a need to improve the understanding of the differences, in terms of health, between the sexes and to translate that knowledge into improved medical diagnostics, practice and therapies. Women's Health Diagnostic Markets analyzes the current and potential world markets for key diagnostic tests targeted at women's health. This report generally forecasts future market growth for these tests to 2018. Market segments covered include the US, Europe, China, Brazil, Japan and rest of world markets. The report presents market developments in women's health diagnostics, including in-depth analysis of the following testing fields: - Pregnancy and Ovulation Testing - Bone Density Testing - Prenatal Screening - Ultrasound - Mammography - Pap Smears - Colposcopy - HPV Testing - Ovarian Cancer Testing - Urinary Tract Infections - Neonatal Jaundice - Autoimmune Disease - Cystic Fibrosis Some of the companies profiled include: - GE Healthcare - GenMark Diagnostics - Hologic - Immco Diagnostics - Luminex - Nova Biomedical - Philips Healthcare - Siemens Healthcare - Somagen Diagnostics Key Topics Covered: 1.0 Executive Summary 2.0 Introduction 3.0 Market Developments in Women's Health Diagnostics 4.0 Pregnancy and Ovulation 5.0 Bone Density Testing 6.0 Prenatal Screening 7.0 Ultrasound 8.0 Mammography 9.0 Pap Smears 10.0 Colposcopy 11.0 HPV Testing 12.0 Ovarian Cancer 13.0 Urinary Tract Infections 14.0 Neonatal Jaundice 15.0 Autoimmune Disease 16.0 Cystic Fibrosis For more information visit http://www.researchandmarkets.com/research/pr8g7c/diagnostic
GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21)
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Wed Nov 05, 3:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum to be held at the Westin Grand Central Hotel in New York, NY on Thursday, November 20, 2014. The presentation will be delivered by Scott Mendel, Chief Financial Officer and is scheduled to begin at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 13.51 (+0.21)
GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 7:14PM CDT
GNMK: 13.51 (+0.21)
GenMark Diagnostics beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:13PM CDT
GNMK: 13.51 (+0.21)
GenMark Diagnostics Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 3:06PM CDT
--Installed Base Grows to 502 Analyzers
GNMK: 13.51 (+0.21)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT
ELLI: 50.06 (+2.67), AIV: 38.55 (-0.50), EPAY: 27.07 (+0.64), CPSI: 53.11 (+0.26), LNKD: 269.00 (+1.83), ADNC: 4.59 (-0.02), CODE: 35.99 (+0.03), HME: 67.76 (-0.96), ESIO: 6.50 (+0.02), HIL: 3.79 (+0.03), DGI: 30.16 (+0.45), AHT: 10.63 (-0.04), COLM: 51.50 (+7.91), AHS: 20.56 (-0.34), CSLT: 9.19 (+0.13), FRT: 143.96 (-0.58), DGII: 10.31 (+0.16), ADUS: 21.57 (+0.18), ESS: 226.69 (-1.30), EXPE: 89.49 (-0.08), IMPV: 43.17 (+1.38), CCI: 88.00 (+0.41), CPT: 75.24 (-1.03), GB: 50.86 (+0.20), AEGR: 25.15 (+0.88), ATEN: 4.14 (-0.09), ELGX: 14.51 (+0.21), AFFX: 11.45 (+0.02), CHE: 107.38 (-0.43), BCOV: 8.43 (+0.27), DCT: 36.70 (+0.23), ELX: 6.57 (+0.22), GNMK: 13.51 (+0.21), AXTI: 2.55 (-0.01), INT: 53.72 (+2.28), EGN: 69.90 (+3.59), EGO: 4.94 (+0.10), GMED: 24.85 (+0.45), GDOT: 15.54 (+0.34), KEG: 2.14 (+0.08), ISBC: 11.70 (+0.07), GRPN: 7.97 (+0.51), ALJ: 13.06 (+0.50), CTRL: 13.39 (+0.10), GPRO: 45.27 (-0.02), EMN: 75.67 (+0.56), IMMR: 9.01 (-0.09), CUBE: 24.28 (-0.32), BYI: 83.27 (unch), ATRC: 18.86 (+0.04), BYD: 14.36 (-0.23), FLDM: 37.93 (-0.47), BEAT: 10.36 (+0.20), FLR: 57.78 (+1.42), FLT: 150.37 (+1.15), EHTH: 10.91 (-0.04)
GenMark reports on October 30
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 3:22PM CDT
GNMK: 13.51 (+0.21)
3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 11:01AM CST
2015 is forecasted to be a transition year for the medical instruments sector.
GNMK: 13.51 (+0.21), DXCM: 62.68 (+0.74), TNDM: 13.16 (+0.25)
Commit To Purchase GenMark Diagnostics At $10, Earn 8.1% Annualized Using Options
at The Street - Mon Feb 09, 10:36AM CST
Investors considering a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $13.02/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GNMK: 13.51 (+0.21)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Will Waters (WAT) Surprise Q4 Earnings on Innovations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 11:50AM CST
Waters Corporation (WAT) is scheduled to report fourth-quarter 2014 results before the opening bell on Jan 27, 2015.
XENT: 23.06 (+0.46), GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21), WAT: 119.86 (+0.71)
Global Diagnostic Markets for Women's Health Market to 2018: Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing
M2 - Fri Jan 16, 9:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/hdjx99/diagnostic) has announced the addition of the "Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)" report to their offering. The women's health arena, both therapeutics and diagnostics, has grown considerably as a specialty medical field. Once limited to obstetrics and gynecology, it now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. At many clinics and practices focused on the health of women, a range of specialties are offered, which often results in a need for specific types of women's health-related testing. Generally, and from a perspective on women's health, diagnostics are playing an ever increasing role. Worldwide, women are living longer than men. There is a need to improve the understanding of the differences, in terms of health, between the sexes and to translate that knowledge into improved medical diagnostics, practice and therapies. Women's Health Diagnostic Markets analyzes the current and potential world markets for key diagnostic tests targeted at women's health. This report generally forecasts future market growth for these tests to 2018. Market segments covered include the US, Europe, China, Brazil, Japan and rest of world markets. Over the next few decades, comprehensive genomics-based health care should be the norm in the US and much of Europe. In the next decade, genetic tests will routinely predict individual susceptibility to disease. Diagnoses of many conditions will be much more thorough and specific than now. The report gives insight into understanding the molecular basis of disease. Women's Health Diagnostic Markets also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Developments in Women's Health Diagnostics 4 Pregnancy and Ovulation 5 Bone Density Testing 6 Prenatal Screening 7 Ultrasound 8 Mammography 9 Pap Smears 10 Colposcopy 11 HPV Testing 12 Ovarian Cancer 13 Urinary Tract Infections 14 Neonatal Jaundice 15 Autoimmune Disease 16 Cystic Fibrosis Companies Mentioned - GE Healthcare - GenMark Diagnostics - Hologic - Immco Diagnostics - Luminex - Nova Biomedical - Philips Healthcare - Siemens Healthcare - Somagen Diagnostics For more information visit http://www.researchandmarkets.com/research/hdjx99/diagnostic
GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21)
GE Extends Debt Financing to GenMark to Spur Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 10:10AM CST
GE Capital's Healtcare Financial Services, a division of General Electric Company (GE), recently augmented the liquidity of GenMark Diagnostics, Inc. (GNMK).
GNMK: 13.51 (+0.21), GD: 137.61 (-0.54), GE: 25.15 (+0.26), NOC: 167.14 (-0.15)
GE Capital's Healthcare Financial Services agents USD40m secured credit facility for GenMark Diagnostics
M2 - Wed Jan 14, 6:04AM CST
GE Capital announced on Tuesday that its Healthcare Financial Services business, a source of capital for the US healthcare market, has served as administrative agent on a senior secured credit facility of up to USD40m for GenMark Diagnostics Inc (Nasdaq:GNMK), a provider of automated, multiplex molecular diagnostic testing systems.
GNMK: 13.51 (+0.21), GE: 25.15 (+0.26)
GE Capital Agents $40 Million Credit Facility for GenMark Diagnostics
Business Wire - Tue Jan 13, 7:00AM CST
GE Capital's Healthcare Financial Services business has served as administrative agent on a senior secured credit facility of up to $40 million for GenMark Diagnostics, Inc. (NASDAQ:GNMK), comprised of a multi-tranched $35 million venture loan facility and a $5 million asset-based revolving credit facility. GE Capital Markets served as sole lead arranger and bookrunner.
GNMK: 13.51 (+0.21), GE: 25.15 (+0.26)
GenMark reports preliminary results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 3:19PM CST
GNMK: 13.51 (+0.21)
GenMark Announces Completion of ePlex(TM) Development and Preliminary Q4 Financial Results
Business Wire - Mon Jan 12, 3:05PM CST
--Fourth Quarter Revenue Expected to be $9.8 million, Up 52% Versus Prior Year
GNMK: 13.51 (+0.21)
GenMark Diagnostics to Present at the 2015 J.P. Morgan Healthcare Conference
Business Wire - Tue Dec 30, 3:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2015 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, CA on Tuesday, January 13, 2015. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 9:30 am Pacific Time. The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 13.51 (+0.21), JPM: 59.67 (+0.10)
Insider Trading Alert - GNMK, RLOG And NBY Traded By Insiders
at The Street - Tue Dec 09, 10:38AM CST
Stocks with insider trader activity include GNMK, RLOG and NBY
GNMK: 13.51 (+0.21), RLOG: 3.59 (unch), NBY: 0.56 (unch)
Molecular Diagnostics in Infectious Disease Testing 2014
M2 - Thu Nov 20, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/zbf7zn/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing 2014" report to their offering. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE For more information visit http://www.researchandmarkets.com/research/zbf7zn/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)
M2 - Tue Nov 18, 4:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/pr8g7c/diagnostic) has announced the addition of the "Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)" report to their offering. The women's health arena, both therapeutics and diagnostics, has grown considerably as a specialty medical field. Once limited to obstetrics and gynecology, it now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. At many clinics and practices focused on the health of women, a range of specialties are offered, which often results in a need for specific types of women's health-related testing. Generally, and from a perspective on women's health, diagnostics are playing an ever increasing role. Worldwide, women are living longer than men. There is a need to improve the understanding of the differences, in terms of health, between the sexes and to translate that knowledge into improved medical diagnostics, practice and therapies. Women's Health Diagnostic Markets analyzes the current and potential world markets for key diagnostic tests targeted at women's health. This report generally forecasts future market growth for these tests to 2018. Market segments covered include the US, Europe, China, Brazil, Japan and rest of world markets. The report presents market developments in women's health diagnostics, including in-depth analysis of the following testing fields: - Pregnancy and Ovulation Testing - Bone Density Testing - Prenatal Screening - Ultrasound - Mammography - Pap Smears - Colposcopy - HPV Testing - Ovarian Cancer Testing - Urinary Tract Infections - Neonatal Jaundice - Autoimmune Disease - Cystic Fibrosis Some of the companies profiled include: - GE Healthcare - GenMark Diagnostics - Hologic - Immco Diagnostics - Luminex - Nova Biomedical - Philips Healthcare - Siemens Healthcare - Somagen Diagnostics Key Topics Covered: 1.0 Executive Summary 2.0 Introduction 3.0 Market Developments in Women's Health Diagnostics 4.0 Pregnancy and Ovulation 5.0 Bone Density Testing 6.0 Prenatal Screening 7.0 Ultrasound 8.0 Mammography 9.0 Pap Smears 10.0 Colposcopy 11.0 HPV Testing 12.0 Ovarian Cancer 13.0 Urinary Tract Infections 14.0 Neonatal Jaundice 15.0 Autoimmune Disease 16.0 Cystic Fibrosis For more information visit http://www.researchandmarkets.com/research/pr8g7c/diagnostic
GNMK: 13.51 (+0.21), HOLX: 30.46 (+0.21)
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Wed Nov 05, 3:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum to be held at the Westin Grand Central Hotel in New York, NY on Thursday, November 20, 2014. The presentation will be delivered by Scott Mendel, Chief Financial Officer and is scheduled to begin at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 13.51 (+0.21)
GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 7:14PM CDT
GNMK: 13.51 (+0.21)
GenMark Diagnostics beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:13PM CDT
GNMK: 13.51 (+0.21)
GenMark Diagnostics Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 3:06PM CDT
--Installed Base Grows to 502 Analyzers
GNMK: 13.51 (+0.21)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT
ELLI: 50.06 (+2.67), AIV: 38.55 (-0.50), EPAY: 27.07 (+0.64), CPSI: 53.11 (+0.26), LNKD: 269.00 (+1.83), ADNC: 4.59 (-0.02), CODE: 35.99 (+0.03), HME: 67.76 (-0.96), ESIO: 6.50 (+0.02), HIL: 3.79 (+0.03), DGI: 30.16 (+0.45), AHT: 10.63 (-0.04), COLM: 51.50 (+7.91), AHS: 20.56 (-0.34), CSLT: 9.19 (+0.13), FRT: 143.96 (-0.58), DGII: 10.31 (+0.16), ADUS: 21.57 (+0.18), ESS: 226.69 (-1.30), EXPE: 89.49 (-0.08), IMPV: 43.17 (+1.38), CCI: 88.00 (+0.41), CPT: 75.24 (-1.03), GB: 50.86 (+0.20), AEGR: 25.15 (+0.88), ATEN: 4.14 (-0.09), ELGX: 14.51 (+0.21), AFFX: 11.45 (+0.02), CHE: 107.38 (-0.43), BCOV: 8.43 (+0.27), DCT: 36.70 (+0.23), ELX: 6.57 (+0.22), GNMK: 13.51 (+0.21), AXTI: 2.55 (-0.01), INT: 53.72 (+2.28), EGN: 69.90 (+3.59), EGO: 4.94 (+0.10), GMED: 24.85 (+0.45), GDOT: 15.54 (+0.34), KEG: 2.14 (+0.08), ISBC: 11.70 (+0.07), GRPN: 7.97 (+0.51), ALJ: 13.06 (+0.50), CTRL: 13.39 (+0.10), GPRO: 45.27 (-0.02), EMN: 75.67 (+0.56), IMMR: 9.01 (-0.09), CUBE: 24.28 (-0.32), BYI: 83.27 (unch), ATRC: 18.86 (+0.04), BYD: 14.36 (-0.23), FLDM: 37.93 (-0.47), BEAT: 10.36 (+0.20), FLR: 57.78 (+1.42), FLT: 150.37 (+1.15), EHTH: 10.91 (-0.04)
GenMark reports on October 30
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 3:22PM CDT
GNMK: 13.51 (+0.21)
